Phio Pharmaceuticals Corp Stock Performance
| PHIO Stock | USD 1.20 0.04 3.45% |
The company holds a Beta of 2.35, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Phio Pharmaceuticals will likely underperform. At this point, Phio Pharmaceuticals Corp has a negative expected return of -0.69%. Please make sure to check Phio Pharmaceuticals' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Phio Pharmaceuticals Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Phio Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in December 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:9 | Dividend Date 2020-01-15 | Last Split Date 2024-07-05 |
1 | Disposition of 4111 shares by Robert Bitterman of Phio Pharmaceuticals at 2.32 subject to Rule 16b-3 | 09/11/2025 |
2 | What makes Phio Pharmaceuticals Corp. stock appealing to growth investors - 2025 Support Resistance Free Safe Capital Growth Stock Tips - newser.com | 10/01/2025 |
3 | Is Phio Pharmaceuticals Corp. stock included in top ETFs - Market Growth Summary Growth-Oriented Investment Plans - newser.com | 10/22/2025 |
4 | How currency fluctuations impact Phio Pharmaceuticals Corp. stock - July 2025 Momentum AI Powered Market Trend Analysis - newser.com | 10/28/2025 |
5 | Phio Pharmaceuticals Announces Exercise of Warrants for Approximately 13.4 Million Gross Proceeds | 11/03/2025 |
6 | How currency fluctuations impact Phio Pharmaceuticals Corp. stock - Weekly Stock Summary Risk Adjusted Buy and Sell Alerts - newser.com | 11/05/2025 |
7 | Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program | 11/07/2025 |
8 | Will Phio Pharmaceuticals Corp. stock profit from AI boom - 2025 Volume Leaders Community Verified Watchlist Alerts - newser.com | 11/11/2025 |
9 | Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress | 11/17/2025 |
10 | Phio Pharmaceuticals Corp files for offering of up to 11.8 million common shares by the Selling Stockholders - SEC filing - MarketScreener | 11/20/2025 |
11 | Insider Trading | 11/21/2025 |
12 | Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | 11/25/2025 |
| Begin Period Cash Flow | 8.5 M | |
| Total Cashflows From Investing Activities | 8000.00 |
Phio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 198.00 in Phio Pharmaceuticals Corp on August 28, 2025 and sell it today you would lose (78.00) from holding Phio Pharmaceuticals Corp or give up 39.39% of portfolio value over 90 days. Phio Pharmaceuticals Corp is currently does not generate positive expected returns and assumes 4.5144% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Phio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Phio Pharmaceuticals Corp, and traders can use it to determine the average amount a Phio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1531
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PHIO |
Estimated Market Risk
| 4.51 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.69 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Phio Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Phio Pharmaceuticals by adding Phio Pharmaceuticals to a well-diversified portfolio.
Phio Pharmaceuticals Fundamentals Growth
Phio Stock prices reflect investors' perceptions of the future prospects and financial health of Phio Pharmaceuticals, and Phio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phio Stock performance.
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 4.19 M | ||||
| Shares Outstanding | 11.04 M | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.29 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (3.59 M) | ||||
| EBITDA | (7.38 M) | ||||
| Net Income | (7.15 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (7.11 M) | ||||
| Earnings Per Share | (2.09) X | ||||
| Market Capitalization | 15.79 M | ||||
| Total Asset | 5.74 M | ||||
| Retained Earnings | (146.36 M) | ||||
| Working Capital | 4.72 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
About Phio Pharmaceuticals Performance
By examining Phio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Phio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Phio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.25) | (1.31) | |
| Return On Capital Employed | (1.56) | (1.49) | |
| Return On Assets | (1.25) | (1.31) | |
| Return On Equity | (1.51) | (1.44) |
Things to note about Phio Pharmaceuticals Corp performance evaluation
Checking the ongoing alerts about Phio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phio Pharmaceuticals Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phio Pharmaceuticals may become a speculative penny stock | |
| Phio Pharmaceuticals has high historical volatility and very poor performance | |
| Phio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (3.59 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (7.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 |
- Analyzing Phio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Phio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phio Pharmaceuticals' stock. These opinions can provide insight into Phio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.